Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Leukaemia (all types), drawn from the whole corpus: 42 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
133 medicines on record are linked to one of the types below rather than to Leukaemia (all types) itself. Grouped by the type that holds them; each list opens that type's own page.
Adult ALL and TP53-mutated AML still have poor outcomes.
Infant and relapsed childhood leukaemias.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Access to CAR-T and transplant outside rich countries.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Late effects of childhood treatment.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 18 changes by month →When this page itself was last checked or edited.
Ibrutinib delayed progression to symptomatic disease but did not improve survival: five-year overall survival 93.
Relapse-free survival hazard ratio 0.
Bortezomib did not significantly improve four-year event-free survival for the whole group (83.
Blinatumomab consolidation gave two-year disease-free survival of 54.
Bortezomib added to chemotherapy did not improve three-year event-free survival (44.